US/UK/Canada

Share

Pick a time period -
Tags ( Active)

A+ Science Invest AB, InnovationsKapital and Swedestart have invested 45 million SEK in the research company Pharmacore

A+ Science Invest AB, InnovationsKapital and Swedestart have invested 45 million SEK in the research company Pharmacore AB. This investment will provide financing of Pharmacore's development of a new cluster of pharmaceuticals for the treatment of common medical conditions, such as gastritis, functional gastrointestinal complaints, and cardiovascular diseases, such as high blood pressure and heart failure. Pharmacore's activities are based on research conducted by leading scientists in medicinal chemistry, gastrointestinal and cardiovascular research at the Universities of Gothenburg and

A+ Science Invest AB (publ.) Interim Report, 1st January - 30th June 2001

A+ Science Invest AB (publ.) Interim Report, 1st January - 30th June 2001 A+ Science Invest AB (publ.) was formed in October 1997 and a multitude of projects and project ideas, mainly from Göteborg University, have been evaluated, acquired, considerably refined, further documented and developed by A+, successfully creating an increased value. During spring A+ has focused on reaching a point of exit in several projects, some have been further developed, and new projects have been evaluated for the portfolio. The activities of the period can be summarised as follows: · A licence agreement on

A+ Science Invest AB and Carbion OY sign licence agreement regarding Helicobacter pylori

A+ Science Invest AB and Carbion OY sign licence agreement regarding Helicobacter pylori A+ Science Invest AB has entered into an exclusive licence agreement with Carbion OY regarding the development of novel treatments for Helicobacter pylori infections based upon an A+ patent. The licence agreement will generate milestone and royalty payments to A+. Helicobacter pylori infection is one of the most common infectious diseases in the world. It is estimated that between 5% and 10% of the world's population suffer from gastric ulcer at least once during their lifetime. The gastric ulcer is

A+ Science Invest AB, Malaysian Rubber Board and University of Hertfordshire have signed a collaborative agreement regar

A+ Science Invest AB, Malaysian Rubber Board and University of Hertfordshire have signed a collaborative agreement regarding development of Improved Properties of Rubber Trees A+ Science Invest AB, Malaysian Rubber Board and University of Hertfordshire have signed a collaborative agreement aiming at research development and commercialisation of rubber trees and rubber products. The goal of this collaboration is to improve on girthing, to reduce the immaturity period and to increase biomass in rubber trees (Hevea brasiliensis). This will be accomplished by exploiting genes of the PALE

Boo Edgar appointed Managing Director of A+ Science Invest AB (publ.)

+ BOO EDGAR APPOINTED MANAGING DIRECTOR OF A SCIENCE INVEST AB (PUBL.) On September 1, Boo Edgar (52) will assume the position of managing + director of A Science Invest AB. Boo Edgar holds a doctorate in clinical pharmacology from Göteborg University, and brings more than 25 years´ experience from the + pharmaceutical industry to A . At AstraZeneca he was responsible to the head of research for the integration of the R&D functions in Zeneca and Astra, the development of a long term AstraZeneca R&D strategy, as well as for establishing a life cycle strategy for AstraZeneca products,

A+ Science Invest AB announces an agreement with Janssen Pharmaceutica

A+ Science Invest AB announces an agreement with Janssen Pharmaceutica on the use of galantamine in obstructive sleep apnoea A+ Science Invest AB of Sweden announces an agreement with Janssen Pharmaceutica whereby Janssen has acquired the exclusive worldwide license to certain A+ intellectual property rights specifically the development and commercialization of galantamine for the treatment of obstructive sleep apnoea (OSA). Janssen Pharmaceutica N.V. of Belgium is an affiliate of Johnson & Johnson (NYSE: JNJ) of New Brunswick, N.J. Janssen is currently developing galantamine for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top